| __timestamp | Bio-Techne Corporation | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 660772000 |
| Thursday, January 1, 2015 | 119401000 | 736435000 |
| Friday, January 1, 2016 | 140879000 | 775266000 |
| Sunday, January 1, 2017 | 199243000 | 860348000 |
| Monday, January 1, 2018 | 240636000 | 814775000 |
| Tuesday, January 1, 2019 | 264359000 | 942821000 |
| Wednesday, January 1, 2020 | 260583000 | 985616000 |
| Friday, January 1, 2021 | 324951000 | 1061508000 |
| Saturday, January 1, 2022 | 372766000 | 1190423000 |
| Sunday, January 1, 2023 | 378378000 | 1254234000 |
| Monday, January 1, 2024 | 396826000 |
Unleashing insights
In the ever-evolving biotech industry, understanding operational efficiency is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Bio-Techne Corporation and Grifols, S.A. from 2014 to 2023. Over this period, Bio-Techne's SG&A expenses grew by approximately 550%, starting from 6% of Grifols' expenses in 2014 to nearly 32% in 2023. Grifols, on the other hand, saw a steady increase, with expenses peaking at over 1.25 billion in 2023. Notably, Bio-Techne's expenses in 2024 are projected to rise further, while Grifols' data for the same year remains unavailable. This trend highlights Bio-Techne's aggressive expansion strategy, while Grifols maintains a larger, yet stable, operational footprint. Such insights are invaluable for investors and stakeholders aiming to gauge the financial health and strategic direction of these biotech giants.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and Grifols, S.A.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Bio-Techne Corporation
Breaking Down SG&A Expenses: Zoetis Inc. vs Bio-Techne Corporation
Operational Costs Compared: SG&A Analysis of argenx SE and Bio-Techne Corporation
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Cytokinetics, Incorporated
Who Optimizes SG&A Costs Better? Bio-Techne Corporation or Ultragenyx Pharmaceutical Inc.
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Viridian Therapeutics, Inc.
Selling, General, and Administrative Costs: Grifols, S.A. vs Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Grifols, S.A. and Veracyte, Inc.
Grifols, S.A. vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Grifols, S.A. and Arrowhead Pharmaceuticals, Inc.
Comparing SG&A Expenses: Grifols, S.A. vs Travere Therapeutics, Inc. Trends and Insights